Anumana
AI platform decoding the electrocardiogram as a deep predictive tool and biomarker of disease
Platform · Cloud SaaSCompany source
Company profile
About nference
nference is a healthcare AI company that serves as the intelligence layer for clinical research, partnering with leading medical centers to unlock the value of real-world data. The company operates a federated AI network that connects healthcare data across institutions while maintaining patient privacy through its 'Data Under Glass' approach, ensuring data remains within health centers' premises. nference's platform processes over 10 billion radiology images, 20 million digitized pathology slides, 12 million ECG waveforms, 100 million echocardiogram videos, and 1.4 billion clinical notes to create the world's most comprehensive research-ready patient dataset. The company's nSights platform leverages agentic AI, neural networks, natural language processing, and large language models to transform unstructured EMR data into curated, computable insights. nference serves both life sciences companies and health systems, enabling regulatory-grade cohort design, patient journey analysis, biomarker discovery, and advanced statistical analytics across therapeutic areas including cardiology, oncology, immunology, rare diseases, neurology, infectious diseases, and nephrology. The company has also launched venture-backed spinouts including Anumana (ECG-based predictive diagnostics) and Pramana (digital pathology solutions). Founded by CEO Murali Aravamudan and Chief Scientific Officer Dr. Venky Soundararajan, nference is headquartered in Cambridge, Massachusetts, with additional offices in Bangalore, Toronto, and Rochester.
Company description nference official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at nference?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer/Oncology
- Cardiovascular diseases
- Immunological conditions
- Infectious diseases
- Kidney diseases/Nephrology
- Neurological conditions
- Rare diseases
Who it serves
- Clinical Researchers
- Data Scientists
- Health Systems
- Life Sciences companies
- Pharma
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsCanada · India · USA
Company sourceOfficial website
Company milestones
Platform expansion
Launched venture spinouts Anumana (ECG-based predictive diagnostics) and Pramana (digital pathology platform). Published research on GLP-1 therapies and lean muscle mass preservation (2025-2026). Recognized as one of the best places to work by Tech Tribune (2020-2023).
Partnerships
Recorded partners
- Health systems through federated AI network
- Leading medical centers and healthcare systems (unnamed)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
nSights
Agentic AI platform for clinical research with multimodal agents for cohort definition, data analysis, and biomarker prediction
Platform · Cloud SaaSCompany source
nSights Augmented Curation
Large-scale synthesis of text data using validated AI to transform EMR notes into labeled datasets
Software · Cloud SaaSCompany source
nSights Cohort Builder
Rapidly generate regulatory-grade patient cohorts with AI-powered criteria refinement
Software · Cloud SaaSCompany source
nSights Imaging Biomarker Platform
AI-powered computable anatomy platform that transforms medical images into quantitative metrics
Platform · Cloud SaaSCompany source
Nucleus
Advanced data science workbench for healthcare research
Platform · Cloud SaaSCompany source
Pramana
Health technology enabling seamless digital adoption by pathology labs and medical centers
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.npj metabolic health and disease · Sep 1, 2026
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.NPJ cardiovascular health · Jul 10, 2026
Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.The journal of allergy and clinical immunology. Global · Jul 1, 2026
Weight-loss dynamics with tirzepatide versus semaglutide.PNAS nexus · Jun 1, 2026
Use of Machine-Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · Jun 1, 2026
Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic.Advances in therapy · Feb 1, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
10 billion+ radiology images
Comprehensive multimodal dataset
20 million+ digitized pathology slides
Linked to patient records
1.4 billion+ clinical notes
Largest labeled EMR dataset
30,000+ unique clinical biomarkers
Extracted from unstructured data
Cohort to patient to evidence in minutes
Research acceleration vs weeks
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from nference
Recent articles published on nference's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.